Skip to content

Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis

Detection of Causative Agents of Acute Pyelonephritis Using Bacterial Metallophores

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05674032
Enrollment
90
Registered
2023-01-06
Start date
2020-06-24
Completion date
2024-12-31
Last updated
2023-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pyelonephritis, Complicated Urinary Tract Infection

Keywords

metallophores, mass spectrometry, acute pyelonephritis, complicated urinary tract infection, siderophores, yersiniabactin

Brief summary

The project aims to investigate bacterial metallophores as potential diagnostic markers of acute pyelonephritis and complicated urinary tract infections. These secondary metabolites are excreted by pathogenic microorganims in the course of infection for the uptake of iron and other metallic ions from the host. They are species-specific and can be detected in body fluids (including urine) by mass spectrometry. The potential contribution of this project is a culture-independent method for the diagnosis of the causative microbiological agent.

Detailed description

Acute pyelonephritis (AP) is a clinical syndrome characterized by fever, chills, nausea vomiting and costovertebral angle tenderness, bacteriuria and pyuria. The underlying pathophysiology is based on the presence of microbes in the renal parenchyma which may progress to sepsis. Complicated urinary tract infection (cUTI) is one accompanied by abnormalities of the urinary tract or host factors which make the eradication of the infection difficult. The most common etiological agents include gram-negative enteric rods, i.e. E. coli, Klebsiella pneumoniae; and Enterococcus spp. Empirical antibiotic treatment should be targeted once culture and sensitivity results become available. This usually takes 24-48 hours, occasionally even 72 hours. Inadequate antibiotic treatment leads to higher mortality if the etiological agent is of a multi-drug resistant phenotype. Metallophores are a major virulence factor of bacterial pathogens. These are chelating molecules secreted by the microbe for the uptake of iron, copper, and other metals from the host. E.g., siderophores aim at Fe3+ ions removal from the host protein molecules; the complex then adheres to specific extracellular receptors on the microbial cell and is internalized. Yersiniabactin is another metallophore which binds copper. Proteomic analysis using mass spectrometry has been used in the detection of biomarkers for several pathological conditions: renal failure, post-transplant nephropathy, various malignancies etc. Metallophores can be detected by mass spectrometry.

Interventions

None listed

Sponsors

Czech Academy of Sciences
CollaboratorOTHER
Thomayer University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* in-patient with clinical signs and symptoms of AP/cUTI or out-patient with clinical signs and symptoms of acute uncomplicated pyelonephritis or in-patient with no clinical signs of UTI and a negative standard urine culture result

Exclusion criteria

* inability to consent

Design outcomes

Primary

MeasureTime frameDescription
Detection of metallophoresthrough study completion, an average of 1 yearThe detection of metallophores in urine samples
Classification of microorganismsthrough study completion, an average of 1 yearTaxonomic classification of the pathogenic microorganism using its metallophores

Secondary

MeasureTime frameDescription
Metallophores versus culturethrough study completion, an average of 1 yearThe comparison of standard urinary culture results with those obtained from mass spectrometry analysis
Cases versus Controls 1 versus Controls 21 year after study completionThe comparison of the detection of metalophores in cases with AP/cUTI versus acute uncomplicated cystitis versus urinary tract infection-free individuals

Countries

Czechia

Contacts

Primary ContactJan Hrbacek, PhD.
honzahrbacek@gmail.com+420261083688
Backup ContactRoman Zachoval, Prof.
roman.zachoval@ftn.cz+420261083688

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026